Centre forms a high-level task force on coronavirus vaccine, drug testing

The task force would also form clinical cohorts, which would focus on long-term follow up of the disease and its management

lockdown, coronavirus
A man wearing protective suit checks the temperature of people standing in a queue to get free food at IYC headquarters, during the nationwide COVID-19 lockdown, in New Delhi
BS Reporter New Delhi
2 min read Last Updated : Apr 20 2020 | 2:35 AM IST
The government has formed a high-level task force for vaccine and drug testing for coronavirus disease (Covid-19) on Sunday, as the death toll from the pandemic increased to 519 and the cases reached 16,116. 
The objective of the task force is to speed up national and international efforts towards vaccine development to treat Covid, Lav Agarwal, joint secretary, health ministry, said.

The task force — co-chaired by Vinod Paul, member NITI Aayog, and Professor K Vijay Raghavan, principal scientific advisor to the government — will also include representatives of Ayush ministry, Indian Council of Medical Research (ICMR), department of biotechnology, and drug controller general of India, among others. 
Besides, the department of biotechnology would act as a nodal agency “to identify the pathway for vaccine development, monitor progress of efforts at both national and international level in this area, and provide government facilitation, where needed”. 

The task force would also form clinical cohorts, which would focus on long-term follow up of the disease and its management. The government will collect bio-specimen that will form the basis for further drug and vaccine trials. “This is different from sample testing protocol,” Agarwal said. 

The government will take a decision on the relaxations that would be allowed in lockdown curbs in non-containment areas on April 20. As on Sunday, there were 54 districts where no new case had been reported in the past 14 days.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusMedical device industryhealthcare technologiesHealthcare in IndiaCommunicable diseases

Next Story